Valuation: Annexon, Inc.

Market Cap 1B 866M 814M 740M 1.39B 95.9B 1.41B 9.54B 3.73B 48.02B 3.77B 3.68B 160B P/E 2026 *
-5.12x
P/E 2027 * -5.36x
Enterprise Value 912M 788M 740M 673M 1.27B 87.24B 1.29B 8.68B 3.39B 43.69B 3.43B 3.35B 145B EV / Sales 2026 *
-
EV / Sales 2027 * 23.5x
Free-Float
94.44%
Yield 2026 *
-
Yield 2027 * -
1 day+0.57%
1 week-2.22%
Current month+3.83%
1 month-10.19%
3 months+1.54%
6 months+8.18%
Current year+5.38%
1 week 5
Extreme 5
5.45
1 month 4.76
Extreme 4.76
5.92
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 2014-11-30
Director of Finance/CFO 53 2019-05-31
Chief Tech/Sci/R&D Officer 68 2023-07-26
Director TitleAgeSince
Director/Board Member 58 2014-11-30
Director/Board Member 67 2021-02-04
Director/Board Member 56 2020-05-31
Date Insider Type Main position Quantity % Market Cap.
8/10/26 Free

Director

175,000 0.1068%
2/19/26 Free

Chief Technology Officer

312,500 0.2159%
2/19/26 Free

Chief Executive Officer

1,250,000 0.8637%
Change 5-day change 1-year change 3-year change Capi.($)
+0.57%-2.22%+116.80%+90.97% 1B
-1.90%+2.85%+62.82%+104.39% 70.07B
-3.21%-4.32%+31.85%+58.98% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
+3.06%+1.04%+50.32%+12.97% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+0.10%+1.40%+35.36%-19.47% 18.75B
+1.83%+0.28%+18.62%+576.88% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +0.47%+1.53%+59.47%+187.85% 26.47B
Weighted average by Cap. -0.51%+0.54%+50.80%+160.55%

Financials

2026 *2027 *
Net sales - 39.16M 33.83M 31.79M 28.91M 54.35M 3.74B 55.24M 372M 146M 1.88B 147M 144M 6.23B
Net income -210M -182M -171M -155M -292M -20.11B -297M -2B -782M -10.07B -790M -772M -33.47B -210M -181M -170M -155M -291M -20.06B -296M -1.99B -780M -10.04B -787M -770M -33.37B
Net Debt -90.55M -78.21M -73.49M -66.84M -126M -8.66B -128M -861M -337M -4.34B -340M -333M -14.41B -80.71M -69.71M -65.5M -59.57M -112M -7.72B -114M -768M -300M -3.86B -303M -296M -12.84B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
92
Date Price Change Volume
26-08-14 US$5.290 +0.57% 2,990,327
26-08-13 US$5.260 -1.31% 3,122,829
26-08-12 US$5.330 -0.19% 3,950,406
26-08-11 US$5.340 -0.93% 924,795
26-08-10 US$5.390 -0.37% 1,960,169
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.290USD
Average target price
14.71USD
Spread / Average Target
+178.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock